Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and y-aminobutyric acid (GABA)/glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating an Autism Spectrum Disorder (ASD).
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 25/00 - Drugs for disorders of the nervous system
Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and γ-aminobutyric acid (GABA)/glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating neurological disease such as an Autism Spectrum Disorder (ASD).
Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of pervasive developmental disorders, dysautonomia, autism, autism spectrum disorder and neurological disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of pervasive developmental disorders, dysautonomia, autism, autism spectrum disorder and neurological disorders
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac disease. Also described herein is a method for treating a subject with Celiac disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac disease.
Described herein are compositions which include digestive enzymes which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally- or recombinantly-derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, antimicrobials in the nature of antibacterial substances for medical purposes, antifungal preparations and anthelmintics; pharmaceutical preparations, namely, antivirals and anti-inflammatories
42 - Scientific, technological and industrial services, research and design
Goods & Services
Commercial administration of the licensing of pharmaceuticals and medical devices of others Development of pharmaceuticals and medical devices for others
14.
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for the
diagnosis, treatment and prevention of viral, bacterial,
fungal, parasitic metabolic, endocrine, hepatological,
respiratory, nervous system, neurological, gastrointestinal,
digestive, inflammatory, pulmonary, hormonal,
dermatological, psychiatric, addictive, behavioral,
infectious, addictive, musculoskeletal, cardiovascular,
ophthalmic, cardiopulmonary, genitourinary, sexual
dysfunction, oncological and immune system related diseases
and disorders; pharmaceutical preparations for the treatment
and prevention of influenza, coronaviruses, pancreatic
deficiencies, gastrointestinal disease, internal
malabsorption syndromes, autism, autism spectrum disorder,
attention deficit hyperactivity disorder and williams
syndrome; antibacterial, antiviral and antifungal
preparations for skin and wound healing; disinfectants and
antiseptics; antimicrobial cleansers for sanitation
purposes; medical assays for testing of bodily fluids and
tissues for testing of enzymes in humans; biological
preparations for medical testing; diagnostic preparations
for medical purposes; testing kits comprised of medical
diagnostic reagents and assays for testing enzymes and body
fluids for use in disease detection; medical diagnostic
reagents and assays for testing of enzymes and body fluids;
chemical preparations for medical testing; diagnostic
biomarker reagents for medical testing; all the foregoing
for the diagnosis and treatment of viral, bacterial, fungal,
parasitic metabolic, endocrine, hepatological, respiratory,
nervous system, neurological, gastrointestinal, digestive,
inflammatory, pulmonary, hormonal, dermatological,
psychiatric, addictive, behavioral, infectious, addictive,
musculoskeletal, cardiovascular, ophthalmic,
cardiopulmonary, genitourinary, sexual dysfunction,
oncological and immune system related diseases and
disorders. Providing medical and scientific research information in the
field of pharmaceuticals and clinical trials; medical and
pharmaceutical research; development of pharmaceuticals and
medical devices for others; providing temporary use of
non-downloadable computer software that allows users to make
determinations regarding neurological diseases, specifically
baseline staging, data gathering and monitoring of early,
middle and late stage neurological diseases; design and
development of medical assays for others; clinical research
and development of treatments for viral, bacterial, fungal,
parasitic metabolic, endocrine, hepatological, respiratory,
nervous system, neurological, gastrointestinal, digestive,
inflammatory, pulmonary, hormonal, dermatological,
psychiatric, addictive, behavioral, infectious, addictive,
musculoskeletal, cardiovascular, ophthalmic,
cardiopulmonary, genitourinary, sexual dysfunction,
oncological and immune system related diseases and
disorders; clinical research and development of treatments
for the treatment and prevention of influenza,
coronaviruses, pancreatic deficiencies, gastrointestinal
disease, internal malabsorption syndromes, autism, autism
spectrum disorder, attention deficit hyperactivity disorder
and williams syndrome; clinical research and development of
treatments for antibacterial, antiviral, and antifungal
preparations for skin and wound healing; clinical research
and development of disinfectants, antiseptics and
antimicrobial cleansers for sanitation purposes; medical and
scientific research services in the field of digestion and
detection of enzymes or biological substances in the body. Medical testing for diagnostic and treatment purposes;
medical consultations; medical testing for diagnostic
treatment purposes in the fields of viral, bacterial,
fungal, parasitic metabolic, endocrine, hepatological,
respiratory, nervous system, neurological, gastrointestinal,
digestive, inflammatory, pulmonary, hormonal,
dermatological, psychiatric, addictive, behavioral,
infectious, addictive, musculoskeletal, cardiovascular,
ophthalmic, cardiopulmonary, genitourinary, sexual
dysfunction, oncological and immune system related diseases
and disorders; medical testing for diagnostic treatment and
prevention of influenza, coronaviruses, pancreatic
deficiencies, gastrointestinal disease, internal
malabsorption syndromes, autism, autism spectrum disorder,
attention deficit hyperactivity disorder and williams
syndrome; medical diagnostic testing, monitoring and
reporting services; performing diagnosis of diseases.
23.
METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of fungal, hepatological, respiratory, gastrointestinal, digestive, pulmonary, hormonal, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, oncological diseases and disorders; pharmaceutical preparations for the treatment and prevention of influenza, coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, autism, autism spectrum disorder, attention deficit hyperactivity disorder and Williams Syndrome; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral diseases and disorders, namely viral skin infections, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), influenza, coronaviruses; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of bacterial diseases and disorders, namely bacterial skin infections, bacterial infections; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of parasitic diseases and disorders, namely parasitic skin infections; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of metabolic diseases and disorders, namely diabetes, Gaucher disease, Menkes; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of endocrine diseases and disorders, namely growth and thyroid disorders; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of nervous system diseases and disorders, namely encephalitis, epilepsy, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease, dysautonomia, Guilliaine Barre Syndrome; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of neurological diseases and disorders, namely Abulia, Agraphia, Akinetopsia, Alien Hand Syndrome, Allan-Herndon-Dudley Syndrome, Alternating hemiplegia of Childhood, Alzheimer's Disease, Amnesia, Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease), Angelman Syndrome, Anosognosias, Aphasia, Aphantasia, Apraxia, Asomatognosia, Asperger Syndrome, Ataxia, Attention Deficit Hyperactivity Disorder, Auditory Processing Disorder, Autism Spectrum Disorder, Bell's Palsy, Bipolar Disorder, Brain Injury, Brody Myopathy, Canavan Disease, Capgras Delusion, Causalgia, Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy, Central Pain Syndrome, Cephalic Disorder, Cerebral Atrophy, Cerebral Palsy, Charcot-Marie-Tooth Disease, Chorea, Chronic-Fatigue Syndrome, Chronic Pain, Cockayne Syndrome, Congenital Distal Spinal Muscular Atrophy, Congenital Facial Diplegia, Corticobasal Degeneration, Creutzfeldt- Jakob Disease, Cyclothymic Disorder, Dandy-Walker Syndrome, Dawson Disease, Dejerine-Sottas Disease, Delayed Sleep Phase Disorder/Syndrome, Dementia, Developmental Coordination Disorder, Developmental Dyspraxia, Diabetic Neuropathy, Diffuse Myelinoclastic Sclerosis (Schilder's Disease), Disorders of Consciousness, Distal Hereditary Motor Neuropathy Type V, Down Syndrome, Dravet Syndrome, Duchenne Muscular Dystrophy, Dysarthia, Dysautonomia (Autonomic Dysfunction), Dyscalculia, Dysgraphia, Dyskinesia, Dsylexia, Dystonia, Encephalopathy, Encopresis, Enuresis, Epilepsy, Essential Tremor, Exploding Head Syndrome, Fainting, Familial Spastic Paralysis, Hereditary Spastic Paraplegia, Monomelic Amyotrophy, Hirschsprung's Disease, Holmes-Adie Syndrome, HVTL-1 Associated Myelopathy (Tropical Spastic Paraparesis), Huntington's Disease, Hypoalgesia, Hypoesthesia, Inclusion Body Myositis, Joubert Syndrome, Karak Syndrome, Kerans-Sayre Syndrome, Kleine-Levin Syndrome, Kufor-Rakeb Syndrome, Spinal Muscular Atrophy, Lambert-Eaton Myasthenic Syndrome, Learning Disabilities, Leigh Syndrome, Leukodystrophy, Leukoencephalopathy with Vanishing White Matter, Lewy Body Dementia, Lyme Disease, Parkinson's Disease, Machado-Joseph Disease, Microcephaly, Migraines, Guilliane-Barré Syndrome (Acute Inflammatory Demyelinating Polyneuropathy), Acute motor Axonal Neuropathy, Acute Motor and Sensory Axonal Neuropathy, Pharyngeal-cervical-brachial Variant, Miller Fisher Syndrome, Misophonia, Mitochondrial Myopathy, Mobius Syndrome, Monomelic Amyotrophy, Morvan Syndrome, Motor Skills Disorder, Multifocal Motor Neuropathy, Multiple Sclerosis, Multiple System Atrophy, Muscular Dystrophy, Myalgic Encephalomyelitis (Chronic Fatigue Syndrome), Opsoclonus Myoclonus Syndrome, Myoclonus, Myopathy, Myotonia Congenita, Narcolepsy, Neuromyotonia, Neuronal Migration Disorder, Neuropathy, Neurosis, Non-24-Hour Sleep-Wake Disorder, Non-Verbal Learning Disorder, Olivopontocerebellar Atrophy, Opsoclonus Myoclonus Syndrome, Orthostatic Hypotension, Monomelic Amyotrophy, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection, Pantothenate Kinase-Associated Neurodegeneration, Paresthesia, Paroxysmal Attacks, Periodic Paralyses, Peripheral Neuropathy, Pervaisve Development Disorders, Phantom Limb, Phantom Pain, Pick's Disease, Polyneuropathy, Polymicogyria, Posttraumatic Stress Disorder, Postural Hypotension, Postural Orthostatic Tachycardia Syndrome, Prader-Will Syndrome, Primary Lateral Sclerosis, Prion Diseases, Progressive Supranuclear Palsy, Ramsay Hunt Syndrome, Ramsay Hunt Syndrome Type I, Ramsay-Hunt Syndrome Type II, Rapid Eye Movement Sleep Behavior Disorder, Restless Leg Syndrome, Rett Syndrome, Reye Syndrome, Rythmic Movement Disorder, Chorea (Sydenham's Chorea, Chorea Minor, St Vitus Dance), Sandhoff Disease, Sanfilippo Disease, Sensory Processing Disorder, Shy-Drager Syndrome, Sleep Apnea, Spasticity, Spinal Chord Injury, Spinal and Bulbar Muscular Atrophy (Kennedy's Disease), Spinal Muscular Atrophy, Spinocerebellar Ataxia, Progressive Supranuclear Palsy, Stuttering, Binswanger's Disease, Superficial Siderosis, Tardive Dyskinisia, Thalamocortical Dysrhythmia, Myotonia Congenita (Thomsen Disease), Todd's Paresis, Tourette Syndrome, Traumatic Brain Injury, Tremor, Trichotillomania, Tuberous sclerosis complex, Wallenberg's Syndrome (Lateral Medullary Syndrome), Wernicke's Encephalopathy, Williams Syndrome, Wilson's Disease, Zellweger Syndrome; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of inflammatory diseases and disorders, namely inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of dermatological diseases and disorders, namely acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, bacterial skin infections, dermatitis, skin pigmentation diseases, and psoriasis; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of psychiatric diseases and disorders, namely depression, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, bipolar disorders, obsessive compulsive disorder, body misphorbic disorder, and psychoses; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of infectious diseases and disorders, namely respiratory infections, eye infections; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of behavioral diseases and disorders, namely Oppositional Defiant Disorder, Intermittent Explosive Disorder, Conduct Disorder (Childhood-onset type, Adolescent-onset type, Unspecified Onset), Antisocial Personality Disorder, Pyromania, Kleptomania, Other Specified Disruptive, Impulse Control, and Conduct Disorder, Unspecified Disruptive, Impulse Control, and Conduct Disorder, sleep disorders, insomnia; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of physical and psychological addictive diseases and disorders, namely drug and chemical addictions, caffeine addictions, gambling addictions, eating disorders and additions, nicotine addictions; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of sexual dysfunction; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of immune system related diseases and disorders, namely Addison disease, Celiac, Dermatomostis Graves, Multiple Sclerosis, Lupus; pharmaceutical preparations and substances for the diagnosis, treatment and prevention of pharmaceutical preparations for the treatment and prevention of influenza, coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, autism, autism spectrum disorder, attention deficit hyperactivity disorder and Williams Syndrome; antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics, namely disinfectants for medical apparatus and instruments, allpurpose disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes, namely antimicrobial hand-sanitizing preparations, antimicrobials for dermatologic use, antimicrobial handwash; medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; diagnostic biomarkers for in vitro testing for medical use; diagnostic preparations for in vitro testing for medical use; biological preparations made from human blood cells for the treatment of cancer; biological preparations made from human blood cells for use in T-cell immunotherapy; diagnostic preparations for clinical laboratory use; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing, namely medical diagnostic reagents and assays for testing of body fluids, reagents for use in diagnostic tests for medical purposes, reagents for use in testing proteins for medical diagnostic purposes, diagnostic chemical reagents for medical purposes, diagnostic biomarker reagents for medical testing. (1) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; pharmaceutical drug development services; medical product development services for others; product research and development in the field of ethical pharmaceuticals and over-the-counter drugs; providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of influenza, coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, autism, autism spectrum disorder, attention deficit hyperactivity disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body.
(2) Medical testing for diagnostic and treatment purposes; information, advisory and consultancy services in the field of medical treatment services; information, advisory and consultancy services in the field of medical care and analysis services; information, advisory and consultancy services in the field of medical testing services; health care consultancy in the fields of public health, health assessments, and medical clinic services; information, advisory and consultancy services in the field of medical clinic services; medical diagnostic consultations provided via phone; medical diagnostic consultations provided via videoconferencing; medical diagnostic consultations provided through online chat functions; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of influenza, coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, autism, autism spectrum disorder, attention deficit hyperactivity disorder and Williams Syndrome; medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans
A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.
A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac Disease. Also described herein is a method for treating a subject with Celiac Disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac Disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac Disease.
Disclosed in this application are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder. Also disclosed is a method for treating an individual with Schizophrenia or a Schizophreniform Disorder using digestive enzymes and their derivatives to alleviate the symptoms of Schizophrenia or a Schizophreniform Disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator, e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
41.
Methods and compositions for the treatment of symptoms of Williams Syndrome
A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical substances and preparations for the treatment of pervasive developmental disorders, autism, dysautonomia, and neurological disorders, all the foregoing excluding pharmaceutical substances of preparations containing, comprised of, or based on cannabis and cannabinoids including, but not limited to, CBD (CBD means C21 H30O)
43.
Enzyme delivery systems and methods of preparation and use
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.
A61K 38/54 - Mixtures of enzymes or proenzymes covered by more than a single one of groups or
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
51.
Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.
Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. More specifically, the application discloses methods of treating a subject with symptoms of an autistic spectrum disorder (ASD) comprising compositions comprising pancreatic digestive enzymes such as pancreatin, lipase, amylase and protease.
Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. More specifically, the application discloses methods of treating a subject with symptoms of an autistic spectrum disorder (ASD) comprising compositions comprising pancreatic digestive enzymes such as pancreatin, lipase, amylase and protease.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
A method to treat Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes, is disclosed. The method includes the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
Pharmaceutical compositions comprising one or more digestive enzymes and one or more gastrointestinal modulators of acid are provided. The one or more digestive enzymes may be coated, e.g., with a lipid. Also disclosed are methods for their use and controlled delivery in treating individuals with neurological, behavioral, infectious, or genetic diseases or conditions susceptible to treatment with digestive enzymes.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
66.
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator, e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
72.
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES
Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.
Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
75.
Methods and compositions for the treatment of symptoms of Williams Syndrome
A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
